Archives of clinical and medical case reports最新文献_第8页

Can Hormonal Contraceptive Therapy be a useful treatment in Fibromyalgia? A Case Report 激素避孕疗法能有效治疗纤维肌痛吗?病例报告

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550484

A. Musto, M. Camici

引用次数: 0

Guiding the Treatment of Hidradenitis Suppurativa: A Role for Therapeutic Drug Monitoring 指导化脓性汗腺炎的治疗:药物监测的作用

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550443

Charlotte Vanhoutte, T. Hillary, A. Laethem

{"title":"Guiding the Treatment of Hidradenitis Suppurativa: A Role for Therapeutic Drug Monitoring","authors":"Charlotte Vanhoutte, T. Hillary, A. Laethem","doi":"10.26502/acmcr.96550443","DOIUrl":"https://doi.org/10.26502/acmcr.96550443","url":null,"abstract":"Background: Although the precise pathophysiology of Hidradenitis Suppurativa (HS) is yet to be elucidated, involvement of various cytokines has been proposed. Accordingly, the use of biologics has been introduced in the armamentarium and adalimumab is currently the only registered biologic for this indiciation. However, case series for IL-12/23 and IL 23-inhibitors are emerging. In case of therapeutic failure or loss of response to a biological, therapy is often blindly adapted, whereas Therapeutic Drug Monitoring (TDM) might assist in a personalized approach to optimize treatment. TDM has shown to be effective in other inflammatory diseases with overlapping pathogenesis. Methods: We present a case of HS with waning response to first adalimumab and then guselkumab for both of which TDM was performed. Research of the literature was conducted. Results: Our patient showed a waning clinical response that was paralleled by a drop in the Trough Levels (TL), first of adalimumab, then of guselkumab. Literature search showed only scarce data on TDM in HS patients. Conclusion: Future research is warranted to determine optimal serum TL for therapeutic efficacy of the biologicals in the treatment of HS. Arch Clin Med Case Rep 2022; 6 (1): 11-16 DOI: 10.26502/acmcr.96550443 Archives of Clinical and Medical Case Reports 12","PeriodicalId":72280,"journal":{"name":"Archives of clinical and medical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69343471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Calcaneal Inferior Spur Fracture Obvious but Easily Missed 跟骨下距骨折明显但易漏诊

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550449

Ahmedelmustafa A Musa, Alaa A Al-Taie

引用次数: 0

Copper Dressings to the Wound Rescue after Everything Else Failed: Case Report 铜敷料在其他方法都失败后的伤口救援:病例报告

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550499

Cernica Chausha Weitman, Tohar Roth, G. Borkow

引用次数: 0

A Gastrointestinal Toxicity during Low-Dose Methotrexate Treatment in Two Pediatric Patients with Acute Lymphoblastic Leukemia 低剂量甲氨蝶呤治疗2例急性淋巴细胞白血病患儿的胃肠道毒性

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550513

Barbara Faganel Kotnik, Tomaž Prelog, Marko Kavi, Simona Lucija Avin, J. Jazbec, L. Kitanovski, Vita Dolan

{"title":"A Gastrointestinal Toxicity during Low-Dose Methotrexate Treatment in Two Pediatric Patients with Acute Lymphoblastic Leukemia","authors":"Barbara Faganel Kotnik, Tomaž Prelog, Marko Kavi, Simona Lucija Avin, J. Jazbec, L. Kitanovski, Vita Dolan","doi":"10.26502/acmcr.96550513","DOIUrl":"https://doi.org/10.26502/acmcr.96550513","url":null,"abstract":"Low-dose Methotrexate (LD-MTX) and 6-mercaptopurine (6-MP) are used in the maintenance phase of treatment of childhood acute lymphoblastic leukaemia. It was reported that individuals with reduced activity of two of the enzymes involved in the pathway of purine metabolism, thiopurine S-methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15), will be exposed to higher levels of active metabolites and will be at higher risk of side effects, such as myelosupression. Therefore, dosing recommendations for 6-MP based on TPMT and NUDT15 genotype have been approved by FDA and have been published by the Clinical Pharmacogenetics Implementation Consortium and the Ditch Working Group. Though several studies were conducted on the toxicity of LD and HD-MTX in childhood ALL patients, none of the genetic markers so far have been used in MTX therapy protocols due to the lack of a clear association with the response and/or toxicity. We describe two pediatric patients who suffered from gastrointestinal toxicity following peroral administration of LD-MTX during maintenance therapy of ALL that diminished after switching to parenteral administration of the drug.","PeriodicalId":72280,"journal":{"name":"Archives of clinical and medical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69343773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ibrutinib-Associated Life-Threatening Hemorrhage with Subcapsular Renal Hematoma and Hemothorax 伊鲁替尼相关的危及生命的出血伴肾包膜下血肿和血胸

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550480

Pramod Gaudel, Autumn Brubaker, Caitlyn Huang, L. Verkruyse, Chao Huang

{"title":"Ibrutinib-Associated Life-Threatening Hemorrhage with Subcapsular Renal Hematoma and Hemothorax","authors":"Pramod Gaudel, Autumn Brubaker, Caitlyn Huang, L. Verkruyse, Chao Huang","doi":"10.26502/acmcr.96550480","DOIUrl":"https://doi.org/10.26502/acmcr.96550480","url":null,"abstract":"Background: Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) which is FDA approved for treatment of chronic lymphocytic leukemia (CLL) and multiple other B-cell lymphoproliferative disorders. Ibrutinib therapy is associated with increased risk of bleeding. We report an unusual but life-threatening case of hemorrhage with subcapsular renal hematoma and large hemothorax secondary to Ibrutinib. Case Presentation: An 85-year-old male with history of CLL started on a reduced dose of ibrutinib presented with acute onset left sided flank Archives of Clinical and Medical Case Reports and acute kidney failure. Imaging revealed moderate to large left sided pleural effusion and a renal mass concerning for renal neoplasm. He underwent thoracentesis revealing hemothorax. The patient was managed conservatively with intravenous hydration for his acute renal failure, blood transfusions and pain medications. His pain resolved; blood counts eventually stabilized and he was discharged from the hospital. The renal mass was later diagnosed as a large subcapsular renal hematoma after further review by another radiologist who determined that the Hounsfield unit of the mass was consistent with blood. Conclusions: This case illustrates a case of life-threatening hemorrhage that required hospitalization after 2 weeks of initiation of ibrutinib. Hemorrhage can occur despite reduced dose, and can result in hemorrhagic pleural effusion and bleeding in solid organs like the kidney. The presence of sudden large masses in a solid organ in a patient on ibrutinib should elicit the differential of intra-organ hemorrhage. Initiation of ibrutinib should be done cautiously, especially in elderly patients.","PeriodicalId":72280,"journal":{"name":"Archives of clinical and medical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69343815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glioblastoma Multiforme with Long Term Survival 长期存活的多形性胶质母细胞瘤

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550524

A. Zaki, N. -, Yasmin Abdul Rashid, Adnan Abdul Jabbar

{"title":"Glioblastoma Multiforme with Long Term Survival","authors":"A. Zaki, N. -, Yasmin Abdul Rashid, Adnan Abdul Jabbar","doi":"10.26502/acmcr.96550524","DOIUrl":"https://doi.org/10.26502/acmcr.96550524","url":null,"abstract":"Background: GBM is the most common and aggressive primary malignant brain tumor. Despite multimodality approach in the treatment of brain tumor, survival of the patients with GBM remains poor. The median survival of glioblastoma patients is ˷12 months. However, 35% of the patients survives for more than 3 years and are referred to as long-term survivors. When disease progression occurs 6-month progression-free survival (PFS) is usually lower than 15%. Case Presentation: A 68-years-old gentleman presented with a space occupying lesion in right frontoparietal region in March 2011, work up showed space (solid enhancing 4.3 x 4.2 x 2.7 cm & cystic component 3.6 x 3.5 x 3 cm). He underwent craniotomy for excision of the lesion, Post-operaticve scan confirmed gross total resection. Histopathology revealed Glioblastoma Multiforme. He received concomitant chemoradiation (60 Gy/30 Fr) with Temozolomide 75mg/m 2 followed by monthly temozolomide (day 1-5 q 28 day cycle)., He was continued on monthly temozolomide (from July 2011- July 2015) with imaging Q 3 montly which revealed no residual disease. Patient primary oncologist was changed and since there was no residual disease and no evidence of prolong use of TMZ, it was stopped and was put on surveillance. He remained in remission till September 2017, when he developed recurrent disease. . He underwent right redo craniotomy & excision of SOL in November 2017. Histopathology revealed GBM. He was started on monthly temozolomide q 28day cycle from December 2017 till February 2018, interim scans in Feb shows disease progression he then received Bevacizumab and irrinotecan Q3weekly till April 2018 interim scans shows disease progression at his time his clinical condition also deteriorated and was not a candidate for any further systemic treatment hence advised palliative care and patient expired in May 2018. This is a rare case which reported such a long survival in GBM. Conclusion: GBM has poor prognosis however we describe a case with prolong outcome. Tumor biology of the patient might be the key to his differential outcome.","PeriodicalId":72280,"journal":{"name":"Archives of clinical and medical case reports","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69343902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Surgery Training in Pakistan 巴基斯坦心脏外科培训

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550531

M. Aasim

引用次数: 0

CLEC12A: A Promise Target for Cancer Therapy CLEC12A:一个有希望的癌症治疗靶点

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550548

R. Chatterjee, U. Chatterji

{"title":"CLEC12A: A Promise Target for Cancer Therapy","authors":"R. Chatterjee, U. Chatterji","doi":"10.26502/acmcr.96550548","DOIUrl":"https://doi.org/10.26502/acmcr.96550548","url":null,"abstract":"Cancer is the leading cause of mortality in every country in the world [1]. The World Health Organization reported that cancer is one of the major causes of disease-related deaths before the age of 70 [2]. Globally, cancer incidences and mortality is alarming and can often be co-related with the socio-economic development of a given population. This concern was depicted in 4-tier Human Development Index (HDI) of the United Nation [3]. An estimated 19.3 million fresh cases and 10 million deaths were registered globally in 2020. Of these, most new cases are of female breast cancer and maximum mortality rate is of lung cancer among both sexes. The cases of blood cancer are also distressing with 711,795 deaths among 1,278,362 new cases registered in 2020 [4]. Worldwide cancer statistics show disconcerting rates of occurrences and deaths even after recent advances in healthcare. Treatment of cancer continues to beat challenge since it is often difficult to appropriately categorise them, based on their underlying molecular signatures. Therefore, elucidating key signaling markers and their role in different types of cancers is a pre-requisite. Research on the haematological niche has progressed in the recent years [5]. The complexity of the human bone marrow, with context to haematological malignancies, is more difficult to elucidate with the present strategies compared to the niche of solid tumors. There can, however, be few similarities between the two, as the bone marrow is a common site of metastasis of solid tumors too [6]. Relevant information has now been established on solid tumors and their micro-environments, which include immune, endothelial and mesenchymal cells. Albeit a gap in knowledge still exists, the need to discover definite means to interfere with the complex interplay between the niches is imperative to define efficient chemotherapeutic strategies in future.","PeriodicalId":72280,"journal":{"name":"Archives of clinical and medical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69344157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Radiochemotherapy and Immunotherapy for A Tracheal Carcinoma 气管癌的放化疗与免疫治疗

Archives of clinical and medical case reports Pub Date : 2022-01-01 DOI: 10.26502/acmcr.96550551

A. Larnaudie, H. Orliac, N. Deny, C. Naessens, R. Serre, P. Clavère

引用次数: 0